根治性前列腺切除术后生化复发且PSA<0.5 ng/ml的前列腺癌患者中68Ga-PSMA-11 PET/CT的效能及对治疗策略的影响
这项回顾性单中心分析纳入119例根治性前列腺切除术后早期生化复发且PSA 0.2-0.5 ng/ml的前列腺癌患者,评估68Ga-PSMA-11 PET/CT的检出率及对治疗策略的影响。结果显示总体检出率为34.4%,30.2%的患者预定治疗发生改变,作者认为该检查有助于早期复发患者的管理并应纳入常规临床实践。
要点
- 119例根治性前列腺切除术后早期生化复发且PSA<0.5 ng/ml患者中,68Ga-PSMA-11 PET/CT总体检出率为34.4%。
- 根据PET/CT结果,36例(30.2%)患者的预定治疗发生改变,41例阳性患者中36例(87.8%)放疗计划被修改。
- 作者认为68Ga-PSMA-11 PET/CT是早期复发患者管理的有用手段,并应纳入常规临床实践。
核心结论
- 在PSA<0.5 ng/ml的患者系列中,68Ga-PSMA-11 PET/CT检出率为34.4%,意向治疗分析中30.2%的患者预定治疗发生改变。
- 这些数据支持68Ga-PSMA-11 PET/CT是根治性前列腺切除术后早期复发患者管理中有用手段的假说,并应纳入常规临床实践。
研究设计与样本
- 本研究为回顾性单中心分析,纳入2016年3月至2017年7月在本机构研究性新药试验中因生化复发接受68Ga-PSMA-11 PET/CT的患者记录。
- 纳入标准为:根治性前列腺切除作为初始治疗、确诊生化复发、68Ga-PSMA-11 PET/CT时PSA在0.2-0.5 ng/ml范围、复发后未接受挽救性放疗。
- 共纳入119例前列腺癌患者,平均年龄66岁(范围44-78岁),PET/CT时平均PSA为0.34 ng/ml(中位数0.32 ng/ml,标准差±0.09,范围0.20-0.50 ng/ml)。
- 患者队列在不知晓68Ga-PSMA-11 PET/CT结果的情况下,按患者特征和治疗模式分为三个亚组:挽救性放疗(伴或不伴全身治疗)、立体定向体部放疗(伴或不伴全身治疗)和全身治疗。
- 对所有患者结合68Ga-PSMA-11 PET/CT图像重新评估治疗策略,并进行意向治疗分析。
主要发现
- 68Ga-PSMA-11 PET/CT在119例患者中41例为阳性,总体检出率为34.4%。
- 68Ga-PSMA-11摄取部位包括前列腺床3例(2.5%)、盆腔淋巴结21例(17.6%)、腹膜后淋巴结4例(3.4%)和骨骼21例(17.6%)。
- 意向治疗分析中,81例(68.1%)被认为可能仅适合前列腺床挽救性放疗,无患者(0%)适合立体定向体部放疗。
- 根据68Ga-PSMA-11 PET/CT结果,36例(30.2%)的预定治疗发生改变;推荐挽救性放疗70例(58.8%),其中仅前列腺床58例(48.7%),立体定向体部放疗29例(24.4%)。
- 41例68Ga-PSMA-11 PET/CT阳性患者中,36例(87.8%)的预定放疗计划被修改。
关键数值与推荐
- 68Ga-PSMA-11 PET/CT总体检出率为34.4%(41/119)。
- 根据PET/CT结果,30.2%(36/119)的患者预定治疗发生改变。
- 41例阳性患者中87.8%(36/41)的预定放疗计划被修改。
- 按PET/CT结果推荐挽救性放疗70例(58.8%),仅前列腺床58例(48.7%),立体定向体部放疗29例(24.4%)。
临床怎么用
- 作者认为68Ga-PSMA-11 PET/CT是根治性前列腺切除术后早期复发前列腺癌患者管理的有用手段,并应纳入常规临床实践。
- 本研究中心在研究性新药试验框架内对生化复发的前列腺癌患者进行68Ga-PSMA-11 PET/CT检查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The primary aim of this retrospective, single-centre analysis was to assess the performance of 68Ga-PSMA-11 PET/CT in prostate cancer (PCa) patients in early PSA failure after radical prostatectomy (RP). The secondary aim was to assess the potential impact of 68Ga-PSMA-11 PET/CT on treatment strategy. METHODS: 68Ga-PSMA-11 PET/CT is performed in our institution within an investigational new drug (IND) trial in PCa patients with biochemical recurrence (BCR). The records of all patients enrolled between March 2016 and July 2017 were evaluated. These records were retrospectively analysed according to the following inclusion criteria: (a) RP as primary therapy, (b) proven BCR, ©) PSA levels in the range 0.2-0.5 ng/ml at the time of the 68Ga-PSMA-11 PET/CT investigation, and (d) no salvage radiotherapy (S-RT) performed after recurrence. The performance of 68Ga-PSMA-11 PET/CT was evaluated in terms of detection rate on a per-patient and a per-region basis (local vs. distant lesions). We further performed an intention-to-treat (ITT) analysis. The patient cohort was grouped into three subpopulations, blinded to the 68Ga-PSMA-11 PET/CT results, according to the patients' characteristics and different patterns of treatment: (1) S-RT (with or without systemic treatment), (2) stereotactic body radiotherapy (SBRT) (with or without systemic treatment), and (3) systemic treatment. The treatment strategy was re-evaluated for each patient taking into consideration the 68Ga-PSMA-11 PET/CT images. RESULTS: We enrolled 119 PCa patients (mean age 66 years, range 44-78 years) with a mean PSA level at the time of 68Ga-PSMA-11 PET/CT of 0.34 ng/ml (median 0.32 ng/ml, SD ±0.09, range 0.20-0.50 ng/ml). 68Ga-PSMA-1 1 PET/CT was positive in 41 of the 119 patients, resulting in an overall detection rate of 34.4%. 68Ga-PSMA-11 uptake was observed in the prostate bed (3 patients, 2.5%), in the pelvic lymph nodes (21, 17.6%), in the retroperitoneal lymph nodes (4, 3.4%) and in the skeleton (21, 17.6%). Regarding ITT, 81 patients (68.1%) were considered possible candidates for S-RT only in the prostate bed and none of the patients (0%) for SBRT. According to the 68Ga-PSMA-11 PET/CT results, the intended treatment was changed in 36 patients (30.2%). According to the PET/CT results, S-RT was recommended in 70 patients (58.8%), only to the prostate bed in 58 (48.7%) and SBRT in 29 (24.4%). The intended RT planning was modified in 36 (87.8%) of 41 patients with a positive 68Ga-PSMA-11 PET/CT result. CONCLUSION: In our patient series with PSA levels <0.5 ng/ml, 68Ga-PSMA-11 PET/CT had a detection rate of 34.4%. In the ITT analysis, 30.2% of patients had a change in the intended treatment. These data support the hypothesis that 68Ga-PSMA-11 PET/CT is a useful procedure in the management of PCa patients showing early recurrence after RP, and should be implemented in routine clinical practice.
引用
- Farolfi A, Ceci F, Castellucci P, et al. 68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. Eur J Nucl Med Mol Imaging. 2018. PMID: 29905907. doi:10.1007/s00259-018-4066-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。